New drug shows promise for tough Crohn's cases

NCT ID NCT05013905

Completed Disease control Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Source: ClinicalTrials.gov ↗

First seen Apr 25, 2026 · Last updated May 25, 2026 · Updated 5 times

Summary

This study tested a new drug called tulisokibart (PRA023) in 55 people with moderate to severe Crohn's disease who had not responded well to other treatments. The main goals were to check safety and see if the drug could improve gut healing and reduce symptoms. After 12 weeks, some participants could continue treatment for up to 170 weeks to monitor long-term effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Prometheus Biosciences Selected Center

Krakow, 31-501, Poland
Prometheus Biosciences Selected Center

Warsaw, 00-635, Poland
Prometheus Biosciences Selected Center

Warsaw, 52-416, Poland
Prometheus Biosciences Selected Site

Los Angeles, California, 90045, United States
Prometheus Biosciences Selected Site

Los Angeles, California, 90048, United States
Prometheus Biosciences Selected Site

Liberty, Kansas, 64098, United States
Prometheus Biosciences Selected Site

Chesterfield, Michigan, 48047, United States
Prometheus Biosciences Selected Site

Ypsilanti, Michigan, 48197, United States
Prometheus Biosciences Selected Site

St Louis, Missouri, 63141, United States
Prometheus Biosciences Selected Site

Lebanon, New Hampshire, 03756, United States
Prometheus Biosciences Selected Site

New York, New York, 10065, United States
Prometheus Biosciences Selected Site

Garland, Texas, 75044, United States
Prometheus Biosciences Selected Site

Lubbock, Texas, 79410, United States
Prometheus Biosciences Selected Site

Lubbock, Texas, 79424, United States
Prometheus Biosciences Selected Site

San Antonio, Texas, 78229, United States
Prometheus Biosciences Selected Site

Southlake, Texas, 78229, United States
Prometheus Biosciences Selected Site

Tyler, Texas, 75702, United States
Prometheus Biosciences Selected Site

Bellevue, Washington, 98004, United States
Prometheus Biosciences Selected Site

Tacoma, Washington, 98405, United States
Prometheus Biosciences Selected Site

Bankstown, New South Wales, 2146, Australia
Prometheus Biosciences Selected Site

Woolloongabba, Queensland, 4102, Australia
Prometheus Biosciences Selected Site

Adelaide, South Australia, 5000, Australia
Prometheus Biosciences Selected Site

Leuven, 3000, Belgium
Prometheus Biosciences Selected Site

Liège, 4000, Belgium
Prometheus Biosciences Selected Site

London, Ontario, N6A 5W9, Canada
Prometheus Biosciences Selected Site

Brno, Czechia
Prometheus Biosciences Selected Site

Slaný, 274 01, Czechia
Prometheus Biosciences Selected Site

Clichy, 92110, France
Prometheus Biosciences Selected Site

Nice, 06202, France
Prometheus Biosciences Selected Site

Saint-Priest-en-Jarez, 42270, France
Prometheus Biosciences Selected Site

Vandœuvre-lès-Nancy, 54511, France
Prometheus Biosciences Selected Site

Tbilisi, Georgia
Prometheus Biosciences Selected Site

Rzeszów, 35-326, Poland
Prometheus Biosciences Selected Site

Sopot, 81-756, Poland
Prometheus Biosciences Selected Site

Torun, 87-100, Poland
Prometheus Biosciences Selected Site

Warsaw, 03-580, Poland
Prometheus Biosciences Selected Site

Wroclaw, 52-416, Poland

Conditions

Explore the condition pages connected to this study.

CROHN DISEASE